These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31138842)

  • 1. The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.
    Armenteros-Monterroso E; Zhao L; Gasparoli L; Brooks T; Pearce K; Mansour MR; Martens JHA; de Boer J; Williams O
    Leukemia; 2019 Dec; 33(12):2817-2829. PubMed ID: 31138842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
    Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
    Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.
    Takao S; Forbes L; Uni M; Cheng S; Pineda JMB; Tarumoto Y; Cifani P; Minuesa G; Chen C; Kharas MG; Bradley RK; Vakoc CR; Koche RP; Kentsis A
    Elife; 2021 Feb; 10():. PubMed ID: 33527899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes.
    Pattabiraman DR; McGirr C; Shakhbazov K; Barbier V; Krishnan K; Mukhopadhyay P; Hawthorne P; Trezise A; Ding J; Grimmond SM; Papathanasiou P; Alexander WS; Perkins AC; Levesque JP; Winkler IG; Gonda TJ
    Blood; 2014 Apr; 123(17):2682-90. PubMed ID: 24596419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a c-MYB-directed therapeutic for acute myeloid leukemia.
    Clesham K; Walf-Vorderwülbecke V; Gasparoli L; Virely C; Cantilena S; Tsakaneli A; Inglott S; Adams S; Samarasinghe S; Bartram J; Williams G; de Boer J; Williams O
    Leukemia; 2022 Jun; 36(6):1541-1549. PubMed ID: 35368048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia.
    Yusenko MV; Trentmann A; Casolari DA; Abdel Ghani L; Lenz M; Horn M; Dörner W; Klempnauer S; Mootz HD; Arteaga MF; Mikesch JH; D'Andrea RJ; Gonda TJ; Müller-Tidow C; Schmidt TJ; Klempnauer KH
    Oncogene; 2021 Jul; 40(29):4746-4758. PubMed ID: 33958723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptidomimetic blockade of MYB in acute myeloid leukemia.
    Ramaswamy K; Forbes L; Minuesa G; Gindin T; Brown F; Kharas MG; Krivtsov AV; Armstrong SA; Still E; de Stanchina E; Knoechel B; Koche R; Kentsis A
    Nat Commun; 2018 Jan; 9(1):110. PubMed ID: 29317678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.
    Zuber J; Rappaport AR; Luo W; Wang E; Chen C; Vaseva AV; Shi J; Weissmueller S; Fellmann C; Taylor MJ; Weissenboeck M; Graeber TG; Kogan SC; Vakoc CR; Lowe SW
    Genes Dev; 2011 Aug; 25(15):1628-40. PubMed ID: 21828272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of ZFAS1 suppresses the progression of acute myeloid leukemia by regulating microRNA-150/Sp1 and microRNA-150/Myb pathways.
    Gan S; Ma P; Ma J; Wang W; Han H; Chen L; Li X; Wu F; Sun H
    Eur J Pharmacol; 2019 Feb; 844():38-48. PubMed ID: 30502345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
    Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
    Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.
    Yusenko MV; Trentmann A; Andersson MK; Ghani LA; Jakobs A; Arteaga Paz MF; Mikesch JH; Peter von Kries J; Stenman G; Klempnauer KH
    Cancer Lett; 2020 Jun; 479():61-70. PubMed ID: 32014461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m
    Weng H; Huang H; Wu H; Qin X; Zhao BS; Dong L; Shi H; Skibbe J; Shen C; Hu C; Sheng Y; Wang Y; Wunderlich M; Zhang B; Dore LC; Su R; Deng X; Ferchen K; Li C; Sun M; Lu Z; Jiang X; Marcucci G; Mulloy JC; Yang J; Qian Z; Wei M; He C; Chen J
    Cell Stem Cell; 2018 Feb; 22(2):191-205.e9. PubMed ID: 29290617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone acetyltransferase TIP60 interacts with c-Myb and inactivates its transcriptional activity in human leukemia.
    Zhao H; Jin S; Gewirtz AM
    J Biol Chem; 2012 Jan; 287(2):925-34. PubMed ID: 22110127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in multiple domains of c-Myb disrupt interaction with CBP/p300 and abrogate myeloid transforming ability.
    Pattabiraman DR; Sun J; Dowhan DH; Ishii S; Gonda TJ
    Mol Cancer Res; 2009 Sep; 7(9):1477-86. PubMed ID: 19737967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C/EBPβ sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module.
    Klempnauer KH
    Exp Hematol; 2022 Apr; 108():8-15. PubMed ID: 35032593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells.
    Uttarkar S; Piontek T; Dukare S; Schomburg C; Schlenke P; Berdel WE; Müller-Tidow C; Schmidt TJ; Klempnauer KH
    Mol Cancer Ther; 2016 Dec; 15(12):2905-2915. PubMed ID: 27707899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression.
    Coulibaly A; Haas A; Steinmann S; Jakobs A; Schmidt TJ; Klempnauer KH
    PLoS One; 2018; 13(2):e0190934. PubMed ID: 29394256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.
    Uttarkar S; Dassé E; Coulibaly A; Steinmann S; Jakobs A; Schomburg C; Trentmann A; Jose J; Schlenke P; Berdel WE; Schmidt TJ; Müller-Tidow C; Frampton J; Klempnauer KH
    Blood; 2016 Mar; 127(9):1173-82. PubMed ID: 26631113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of RUVBL1-RUVBL2 AAA-ATPases by the nonsense-mediated mRNA decay factor DHX34, as evidenced by Cryo-EM.
    López-Perrote A; Hug N; González-Corpas A; Rodríguez CF; Serna M; García-Martín C; Boskovic J; Fernandez-Leiro R; Caceres JF; Llorca O
    Elife; 2020 Nov; 9():. PubMed ID: 33205750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations.
    Volpe G; Cauchy P; Walton DS; Ward C; Blakemore D; Bayley R; Clarke ML; Schmidt L; Nerlov C; Garcia P; Dumon S; Grebien F; Frampton J
    Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30877232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.